BIOMARIN PHARMACEUTICAL INC

Form 4

August 05, 2008

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF

SECURITIES

OMB Number:

3235-0287

January 31, Expires:

2005

0.5

Estimated average burden hours per

OMB APPROVAL

response...

Section 16. Form 4 or Form 5 obligations may continue. See Instruction

Check this box

if no longer

subject to

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section

30(h) of the Investment Company Act of 1940

1(b).

(Print or Type Responses)

1. Name and Address of Reporting Person * 5. Relationship of Reporting Person(s) to 2. Issuer Name and Ticker or Trading KAKKIS EMIL D Issuer Symbol **BIOMARIN PHARMACEUTICAL** (Check all applicable) INC [BMRN] (Last) (First) (Middle) 3. Date of Earliest Transaction Director

(Month/Day/Year)

08/01/2008

10% Owner X_ Officer (give title Other (specify below)

Chief Medical Officer

C/O BIOMARIN PHARMACEUTICAL INC., 3105 DIGITAL DRIVE

> (Street) 4. If Amendment, Date Original

Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check

Applicable Line)

X Form filed by One Reporting Person Form filed by More than One Reporting Person

NOVATO, CA 94949

(City)	(State)	(Zip) Tab	le I - Non-	Derivativo	e Secu	rities Acqui	red, Disposed of,	or Beneficiall	y Owned
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securi cor Dispo (Instr. 3,	sed of 4 and (A)		5. Amount of Securities Beneficially Owned Following Reported Transaction(s)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code V	Amount	or (D)	Price	(Instr. 3 and 4)		
Common Stock	08/01/2008(1)	08/01/2008	S	100	D	\$ 32.465	145,204	D	
Common Stock	08/01/2008(1)	08/01/2008	S	100	D	\$ 32.48	145,104	D	
Common Stock	08/01/2008(1)	08/01/2008	S	100	D	\$ 32.53	145,004	D	
Common Stock	08/01/2008(1)	08/01/2008	S	1,900	D	\$ 32.513	143,104	D	
	08/01/2008(1)	08/01/2008	S	1,000	D	\$ 32.51	142,104	D	

Edgar Filing: BIOMARIN PHARMACEUTICAL INC - Form 4

Common Stock								
Common Stock	08/01/2008(1)	08/01/2008	S	5,300	D	\$ 32.5	136,804	D
Common Stock	08/01/2008(1)	08/01/2008	S	100	D	\$ 32.49	136,704	D
Common Stock	08/01/2008(1)	08/01/2008	S	100	D	\$ 32.42	136,604	D
Common Stock	08/01/2008(1)	08/01/2008	S	300	D	\$ 32.47	136,304	D
Common Stock	08/01/2008(1)	08/01/2008	S	100	D	\$ 32.5062	136,204	D
Common Stock	08/01/2008(1)	08/01/2008	S	100	D	\$ 32.4575	136,104	D
Common Stock	08/01/2008(1)	08/01/2008	S	400	D	\$ 32.455	135,704	D
Common Stock	08/01/2008(1)	08/01/2008	S	200	D	\$ 32.43	135,504	D
Common Stock	08/01/2008(1)	08/01/2008	S	200	D	\$ 32.44	135,304	D
Common Stock	08/01/2008(1)	08/01/2008	S	100	D	\$ 32.34	135,204	D
Common Stock	08/01/2008(1)	08/01/2008	S	300	D	\$ 32.4503	134,904	D
Common Stock	08/01/2008(1)	08/01/2008	S	2,000	D	\$ 32.46	132,904	D
Common Stock	08/01/2008(1)	08/01/2008	S	1,100	D	\$ 32.4525	131,804	D
Common Stock	08/01/2008(1)	08/01/2008	S	4,500	D	\$ 32.45	127,304	D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of	2.	3. Transaction Date	3A. Deemed	4.	5.	6. Date Exercisable and	7. Title and	8. Price of	9. Nu
Derivative	Conversion	(Month/Day/Year)	Execution Date, if	Transactio	onNumber	Expiration Date	Amount of	Derivative	Deriv
Security	or Exercise		any	Code	of	(Month/Day/Year)	Underlying	Security	Secui
(Instr. 3)	Price of		(Month/Day/Year)	(Instr. 8)	Derivativ	e	Securities	(Instr. 5)	Bene

Edgar Filing: BIOMARIN PHARMACEUTICAL INC - Form 4

Derivative Securities (Instr. 3 and 4)

Acquired
(A) or
Disposed
of (D)

(Instr. 3, 4, and 5)

Code V (A) (D) Date Expiration Title Amount

Exercisable Date

or Number of Shares Own

Follo

Repo

Trans

(Insti

Reporting Owners

Security

Reporting Owner Name / Address Relationships

Director 10% Owner Officer Other

KAKKIS EMIL D C/O BIOMARIN PHARMACEUTICAL INC. 3105 DIGITAL DRIVE NOVATO, CA 94949

Chief Medical Officer

Signatures

G. Eric Davis, Attorney-in-Fact

**Signature of Reporting Person Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Transaction made pursuant to a Rule10b5-1 Trading Plan executed March 1, 2008.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Reporting Owners 3